Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) was submitted on May 11, 2022. The report covers the six-month period from November 1, 2021, to April 30, 2022. The document serves as a Block Listing Six Monthly Return detailing the status of specific employee share incentive schemes.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the administration of equity compensation plans rather than consolidated financial performance.
Share Scheme Activity
| Scheme Name | Securities Issued/Allotted | Balance Unallotted (End of Period) |
|---|---|---|
| 2017 Deferred Annual Bonus Plan | 221,300 | 44,219 |
| Share Save Plan 2012 | 1,695,652 | 1,373,495 |
Material Changes
During the reporting period, no increases were applied for to the block schemes. The primary activity consisted of the allotment of securities under existing plans, reducing the balance of unallotted securities for both the Deferred Annual Bonus Plan and the Share Save Plan 2012.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The document is a regulatory disclosure regarding share scheme mechanics.
Key Facts for Investor Verification
- Verify the total number of shares issued under the 2017 Deferred Annual Bonus Plan (221,300) and the Share Save Plan 2012 (1,695,652) against the company's broader equity dilution metrics.
- Confirm the remaining unallotted balances (44,219 and 1,373,495 respectively) to assess future potential share issuance capacity under these specific schemes.
- Note that this filing contains no financial performance data; investors should refer to the company's Form 20-F or interim financial reports for revenue and profit figures.